NYSE:MRKMerck & Co., Inc. Stock Price, Forecast & News

Merck & Co., Inc.'s stock was trading at $79.25 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, MRK shares have decreased by 0.6% and is now trading at $78.78. View which stocks have been most impacted by Coronavirus.

13 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Merck & Co., Inc. in the last year. There are currently 2 hold ratings and 11 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Merck & Co., Inc..

Merck & Co., Inc. is scheduled to release its next quarterly earnings announcement on Friday, July 31st 2020. View our earnings forecast for Merck & Co., Inc..

Merck & Co., Inc. will be holding an earnings conference call on Friday, July 31st at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

Merck & Co., Inc. (NYSE:MRK) issued its earnings results on Tuesday, April, 28th. The company reported $1.50 EPS for the quarter, beating the Thomson Reuters' consensus estimate of $1.34 by $0.16. The business earned $12.06 billion during the quarter, compared to the consensus estimate of $11.46 billion. Merck & Co., Inc. had a net margin of 21.10% and a return on equity of 52.46%. Merck & Co., Inc.'s revenue was up 11.5% on a year-over-year basis. During the same period last year, the business earned $1.22 earnings per share. View Merck & Co., Inc.'s earnings history.

Merck & Co., Inc. announced a quarterly dividend on Tuesday, May 26th. Shareholders of record on Monday, June 15th will be given a dividend of $0.61 per share on Tuesday, July 7th. This represents a $2.44 annualized dividend and a dividend yield of 3.10%. The ex-dividend date of this dividend is Friday, June 12th. View Merck & Co., Inc.'s dividend history.

Merck & Co., Inc. declared that its Board of Directors has initiated a share buyback program on Thursday, October 25th 2018, which authorizes the company to repurchase $10,000,000,000.00 in shares, according to EventVestor. This repurchase authorization authorizes the company to purchase up to 5.1% of its stock through open market purchases. Stock repurchase programs are usually an indication that the company's management believes its stock is undervalued.

Merck & Co., Inc. issued an update on its FY 2020 Pre-Market earnings guidance on Tuesday, April, 28th. The company provided EPS guidance of 5.17-5.37 for the period, compared to the Thomson Reuters consensus EPS estimate of $5.56. The company issued revenue guidance of $46.1-48.1 billion, compared to the consensus revenue estimate of $48.72 billion.

13 analysts have issued 1-year target prices for Merck & Co., Inc.'s shares. Their forecasts range from $89.00 to $105.00. On average, they anticipate Merck & Co., Inc.'s stock price to reach $94.15 in the next twelve months. This suggests a possible upside of 19.5% from the stock's current price. View analysts' price targets for Merck & Co., Inc..

News headlines about MRK stock have been trending somewhat negative this week, according to InfoTrie. The research group identifies positive and negative news coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Merck & Co., Inc. earned a daily sentiment score of -1.0 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, indicating that recent news coverage is extremely unlikely to have an impact on the stock's share price in the next several days. View the latest news about Merck & Co., Inc..

Merck & Co., Inc. saw a decline in short interest in June. As of June 15th, there was short interest totaling 15,810,000 shares, a decline of 16.7% from the May 31st total of 18,990,000 shares. Based on an average daily trading volume, of 12,760,000 shares, the short-interest ratio is presently 1.2 days. Approximately 0.6% of the shares of the stock are sold short. View Merck & Co., Inc.'s Current Options Chain.

Some companies that are related to Merck & Co., Inc. include Johnson & Johnson (JNJ), Pfizer (PFE), Eli Lilly And Co (LLY), AbbVie (ABBV), Bristol-Myers Squibb (BMY), Zoetis (ZTS), Royalty Pharma (RPRX), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX), Corcept Therapeutics (CORT) and Zogenix (ZGNX). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Merck & Co., Inc. investors own include Pfizer (PFE), Johnson & Johnson (JNJ), AT&T (T), Intel (INTC), Walt Disney (DIS), Cisco Systems (CSCO), JPMorgan Chase & Co. (JPM), Verizon Communications (VZ), AbbVie (ABBV) and Exxon Mobil (XOM).

Merck & Co., Inc. trades on the New York Stock Exchange (NYSE) under the ticker symbol "MRK."

Merck & Co., Inc.'s stock is owned by many different institutional and retail investors. Top institutional investors include Cacti Asset Management LLC (0.03%), Park National Corp OH (0.01%), First Financial Bank Trust Division (0.00%), Thomasville National Bank (0.00%), Cox Capital Mgt LLC (0.00%) and Gantzert Investment Co. LLC ADV (0.00%). Company insiders that own Merck & Co., Inc. stock include Adam H Schechter, Ashley Watson, Frank Clyburn, Julie L Gerberding, Kenneth C Frazier, Leslie A Brun, Merck & Co, Inc, Richard R Deluca, Rita A Karachun, Robert M Davis, Roger M Perlmutter, Sanat Chattopadhyay, Thomas H Glocer and Wendell P Weeks. View institutional ownership trends for Merck & Co., Inc..

MRK stock was sold by a variety of institutional investors in the last quarter, including Cacti Asset Management LLC, Park National Corp OH, M&R Capital Management Inc., First Financial Bank Trust Division, and Nelson Van Denburg & Campbell Wealth Management Group LLC. Company insiders that have sold Merck & Co., Inc. company stock in the last year include Julie L Gerberding, Richard R Deluca, and Wendell P Weeks. View insider buying and selling activity for Merck & Co., Inc..

MRK stock was acquired by a variety of institutional investors in the last quarter, including Red Spruce Capital LLC, Cox Capital Mgt LLC, Gantzert Investment Co. LLC ADV, Thomasville National Bank, Modus Advisors LLC, and Ellenbecker Investment Group. View insider buying and selling activity for Merck & Co., Inc..

Shares of MRK can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of MRK stock can currently be purchased for approximately $78.78.

Merck & Co., Inc. has a market capitalization of $198.85 billion and generates $46.84 billion in revenue each year. The company earns $9.84 billion in net income (profit) each year or $5.19 on an earnings per share basis. Merck & Co., Inc. employs 71,000 workers across the globe.

The official website for Merck & Co., Inc. is www.merck.com.

Merck & Co., Inc.'s mailing address is 2000 GALLOPING HILL ROAD, KENILWORTH NJ, 07033. The company can be reached via phone at 908-740-4000 or via email at [email protected]